Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...
UK-based AstraZeneca’s acquired rare disease drug has met the primary endpoint in a Phase III trial in patients with chronic hypoparathyroidism. The Calypso trial (NCT05778071) of eneboparatide, an ...
4d
allAfrica.com on MSNBeyond dispensing, drive research for better drug efficacy – Experts tell pharmacistsBy Chioma Obinna Scientists have called on pharmacists to prioritise research and ethical practice over immediate financial ...
But if we can’t ban pharmaceutical ads, we can at least rein them in. Policymakers can play an integral role in addressing the manipulative advertising practices rampant in the industry, while still ...
Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...
GlobalData on MSN1d
Scholar Rock SMA drug shows muscle function benefitScholar Rock’s spinal muscular atrophy (SMA) therapy has shown benefit in muscle function in children under 12 in a pivotal ...
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
The FDA has granted orphan drug designation to PEP-010 for pancreatic cancer, advancing its development as a potential novel ...
Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment paradigms in ovarian cancer.
Scientists have called on pharmacists to prioritise research and ethical practice over immediate financial gain, stressing that the cornerstone of effective pharmacy practice lies in rigorous ...
1d
The Pioneer on MSNPar panel recommends single independent drug controller for AYUSHNew Delhi, A parliamentary committee has recommended the consolidation of all AYUSH drug-related standard-setting processes under a single independent drug controller in alignment with the Drugs and ...
On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results